Opaleye Management Inc., a ten percent owner of Harrow, Inc. (NASDAQ:HROW), recently sold 20,000 shares of the pharmaceutical ...
Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development ...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, ...